| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Bimagrumab | BYM-338; LY-3985863 | Phase 2 Clinical | Novartis Pharma Ag | Diabetes Mellitus, Type 2; Myositis, Inclusion Body; Obesity; Pulmonary Disease, Chronic Obstructive; Sarcopenia | Details |
| HS135 | HS-135 | Phase 2 Clinical | 35Pharma Inc | Hypertension, Pulmonary; Pulmonary Arterial Hypertension | Details |
| BIIB-110 | BIIB-110; BIIB110; ALG-801 | Phase 1 Clinical | Alivegen USA Inc | Muscular Diseases; Muscular Atrophy, Spinal | Details |
| LAE-123 | LAE-123 | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



